• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一名囊性纤维化患儿的多重耐药铜绿假单胞菌感染

Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis.

作者信息

Ang Jocelyn Y, Abdel-Haq Nahed, Zhu Frank, Thabit Abrar K, Nicolau David P, Satlin Michael J, van Duin David

机构信息

Division of Infectious Diseases, Children's Hospital of Michigan, Detroit, Michigan, USA Department of Pediatrics, Wayne State University School of Medicine, Detroit, Michigan, USA

Division of Infectious Diseases, Children's Hospital of Michigan, Detroit, Michigan, USA Department of Pediatrics, Wayne State University School of Medicine, Detroit, Michigan, USA.

出版信息

Antimicrob Agents Chemother. 2016 Sep 23;60(10):5627-30. doi: 10.1128/AAC.00705-16. Print 2016 Oct.

DOI:10.1128/AAC.00705-16
PMID:27664282
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5038228/
Abstract

We describe a pediatric cystic fibrosis patient who developed a pulmonary exacerbation due to two multidrug-resistant (MDR) Pseudomonas aeruginosa isolates. In addition to these MDR organisms, the case was further complicated by β-lactam allergy. Despite the MDR phenotype, both isolates were susceptible to an antimicrobial combination.

摘要

我们描述了一名儿科囊性纤维化患者，该患者因两种耐多药（MDR）铜绿假单胞菌分离株而出现肺部病情加重。除了这些耐多药微生物外，该病例还因β-内酰胺过敏而进一步复杂化。尽管具有耐多药表型，但两种分离株均对一种抗菌药物组合敏感。

相似文献

1
Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis.一名囊性纤维化患儿的多重耐药铜绿假单胞菌感染
Antimicrob Agents Chemother. 2016 Sep 23;60(10):5627-30. doi: 10.1128/AAC.00705-16. Print 2016 Oct.
2
Ceftolozane/tazobactam sensitivity patterns in Pseudomonas aeruginosa isolates recovered from sputum of cystic fibrosis patients.从囊性纤维化患者痰液中分离出的铜绿假单胞菌菌株对头孢洛赞/他唑巴坦的敏感性模式。
Diagn Microbiol Infect Dis. 2018 Sep;92(1):75-77. doi: 10.1016/j.diagmicrobio.2018.05.002. Epub 2018 May 12.
3
Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-Resistant Pseudomonas aeruginosa.成功使用头孢洛扎/他唑巴坦治疗由多重耐药铜绿假单胞菌引起的囊性纤维化肺部加重期
Pharmacotherapy. 2016 Oct;36(10):e154-e159. doi: 10.1002/phar.1825. Epub 2016 Sep 1.
4
Relevance of multidrug-resistant Pseudomonas aeruginosa infections in cystic fibrosis.多重耐药铜绿假单胞菌感染在囊性纤维化中的相关性。
Int J Med Microbiol. 2017 Sep;307(6):353-362. doi: 10.1016/j.ijmm.2017.07.004. Epub 2017 Jul 19.
5
The clinical significance of pneumonia in patients with respiratory specimens harbouring multidrug-resistant Pseudomonas aeruginosa: a 5-year retrospective study following 5667 patients in four general ICUs.呼吸标本中携带多重耐药铜绿假单胞菌的肺炎患者的临床意义：4 个综合 ICU 中 5667 例患者 5 年回顾性研究。
Eur J Clin Microbiol Infect Dis. 2017 Nov;36(11):2155-2163. doi: 10.1007/s10096-017-3039-z. Epub 2017 Jun 17.
6
Role of efflux pumps: MexAB-OprM and MexXY(-OprA), AmpC cephalosporinase and OprD porin in non-metallo-β-lactamase producing Pseudomonas aeruginosa isolated from cystic fibrosis and burn patients.外排泵的作用：MexAB - OprM和MexXY（- OprA）、AmpC头孢菌素酶及OprD孔蛋白在从囊性纤维化患者和烧伤患者中分离出的非产金属β - 内酰胺酶铜绿假单胞菌中的作用
Infect Genet Evol. 2014 Jun;24:187-92. doi: 10.1016/j.meegid.2014.03.018. Epub 2014 Mar 30.
7
Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam.用头孢他啶/他唑巴坦成功治疗多重耐药铜绿假单胞菌突破性菌血症。
Infection. 2017 Feb;45(1):115-117. doi: 10.1007/s15010-016-0944-5. Epub 2016 Sep 26.
8
In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.头孢吡肟、哌拉西林-他唑巴坦或美罗培南与环丙沙星联合治疗对多重耐药铜绿假单胞菌菌株的体外活性。
Chemotherapy. 2003 Dec;49(6):294-7. doi: 10.1159/000074529.
9
Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.发热性中性粒细胞减少症儿童和青少年铜绿假单胞菌血症的临床特征、结局及抗生素耐药性的影响：一项回顾性研究
BMC Infect Dis. 2017 Jul 17;17(1):500. doi: 10.1186/s12879-017-2597-0.
10
Penicillin-binding protein 3 is a common adaptive target among Pseudomonas aeruginosa isolates from adult cystic fibrosis patients treated with β-lactams.青霉素结合蛋白 3 是接受β-内酰胺类药物治疗的成年囊性纤维化患者分离的铜绿假单胞菌中的常见适应性靶位。
Int J Antimicrob Agents. 2019 May;53(5):620-628. doi: 10.1016/j.ijantimicag.2019.01.009. Epub 2019 Jan 19.

引用本文的文献

1
Ceftolozane/Tazobactam for the Treatment of Adults With Cystic Fibrosis: Results From a French Prospective Cohort Study.头孢洛扎/他唑巴坦治疗成人囊性纤维化：一项法国前瞻性队列研究的结果
Open Forum Infect Dis. 2024 Aug 6;11(8):ofae391. doi: 10.1093/ofid/ofae391. eCollection 2024 Aug.
2
Novel Beta Lactam Antibiotics for the Treatment of Multidrug-Resistant Gram-Negative Infections in Children: A Narrative Review.用于治疗儿童多重耐药革兰氏阴性菌感染的新型β-内酰胺类抗生素：一项叙述性综述
Microorganisms. 2023 Jul 13;11(7):1798. doi: 10.3390/microorganisms11071798.
3
Ceftolozane-Tazobactam against Pseudomonas aeruginosa Cystic Fibrosis Clinical Isolates in the Hollow-Fiber Infection Model: Challenges Imposed by Hypermutability and Heteroresistance.头孢洛扎他唑巴坦对囊性纤维化临床分离的铜绿假单胞菌在中空纤维感染模型中的作用：高突变率和异质性耐药带来的挑战。
Antimicrob Agents Chemother. 2023 Aug 17;67(8):e0041423. doi: 10.1128/aac.00414-23. Epub 2023 Jul 10.
4
A Rapid and Sensitive Detection Method for Using Visualized Recombinase Polymerase Amplification and Lateral Flow Strip Technology.可视化重组酶聚合酶扩增和侧向流条技术的快速灵敏检测方法。
Front Cell Infect Microbiol. 2021 Sep 14;11:698929. doi: 10.3389/fcimb.2021.698929. eCollection 2021.
5
Ceftolozane/Tazobactam for Resistant Drugs Respiratory Infections: A Systematic Literature Review of the Real-World Evidence.头孢洛扎/他唑巴坦用于耐药菌引起的呼吸道感染：真实世界证据的系统文献综述
Life (Basel). 2021 May 24;11(6):474. doi: 10.3390/life11060474.
6
Ceftolozane/Tazobactam for Treating Children With Exacerbations of Cystic Fibrosis Due to : A Review of Available Data.头孢洛扎/他唑巴坦用于治疗儿童囊性纤维化急性加重：现有数据综述
Front Pediatr. 2020 May 5;8:173. doi: 10.3389/fped.2020.00173. eCollection 2020.
7
Nosocomial Chronic Osteomyelitis of the Tibia in an Otherwise Healthy Adolescent: A Case Report.一名健康青少年的医院获得性胫骨慢性骨髓炎：病例报告
J Orthop Case Rep. 2019;9(4):71-75. doi: 10.13107/jocr.2019.v09.i04.1486.
8
Carbapenem-Resistant Gram-Negative Bacterial Infections in Children.儿童耐碳青霉烯类革兰氏阴性菌感染。
Antimicrob Agents Chemother. 2020 Feb 21;64(3). doi: 10.1128/AAC.02183-19.
9
Use of Ceftolozane/tazobactam for the Treatment of Multidrug-resistant Pneumonia in a Pediatric Patient with Combined Immunodeficiency (CID): A Case Report from a Tertiary Hospital in Saudi Arabia.使用头孢洛扎/他唑巴坦治疗合并免疫缺陷（CID）的儿科患者的耐多药肺炎：沙特阿拉伯一家三级医院的病例报告
Antibiotics (Basel). 2019 May 27;8(2):67. doi: 10.3390/antibiotics8020067.
10
Antimicrobial Activity of α-Peptide/β-Peptoid Lysine-Based Peptidomimetics Against Colistin-Resistant Isolated From Cystic Fibrosis Patients.基于α-肽/β-类肽赖氨酸的肽模拟物对从囊性纤维化患者中分离出的耐黏菌素菌株的抗菌活性
Front Microbiol. 2019 Feb 20;10:275. doi: 10.3389/fmicb.2019.00275. eCollection 2019.

本文引用的文献

1
Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations.头孢他啶/阿维巴坦和头孢洛扎/他唑巴坦：第二代β-内酰胺/β-内酰胺酶抑制剂组合
Clin Infect Dis. 2016 Jul 15;63(2):234-41. doi: 10.1093/cid/ciw243. Epub 2016 Apr 20.
2
Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis.头孢洛扎/他唑巴坦、头孢他啶、美罗培南和哌拉西林/他唑巴坦对从囊性纤维化患儿中分离出的铜绿假单胞菌的微生物活性。
Diagn Microbiol Infect Dis. 2015 Sep;83(1):53-5. doi: 10.1016/j.diagmicrobio.2015.04.012. Epub 2015 May 1.
3
Combination treatment with meropenem plus levofloxacin is synergistic against Pseudomonas aeruginosa infection in a murine model of pneumonia.在小鼠肺炎模型中，美罗培南联合左氧氟沙星治疗对铜绿假单胞菌感染具有协同作用。
J Infect Dis. 2015 Apr 15;211(8):1326-33. doi: 10.1093/infdis/jiu603. Epub 2014 Oct 31.
4
Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target.铜绿假单胞菌和肺炎链球菌的最低抑菌浓度（MIC）范围对头孢洛扎因体内药代动力学/药效学靶点的影响。
Antimicrob Agents Chemother. 2014 Oct;58(10):6311-4. doi: 10.1128/AAC.03572-14. Epub 2014 Aug 4.
5
Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination.头孢他啶/阿维巴坦：一种新型抗假单胞菌头孢菌素与β-内酰胺酶抑制剂的组合。
Infect Drug Resist. 2013 Nov 29;6:215-23. doi: 10.2147/IDR.S36140.
6
Pseudomonas aeruginosa: all roads lead to resistance.铜绿假单胞菌：条条大路通耐药。
Trends Microbiol. 2011 Aug;19(8):419-26. doi: 10.1016/j.tim.2011.04.005. Epub 2011 Jun 12.
7
Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients.新头孢菌素 CXA-101（FR264205）对慢性感染囊性纤维化患者分离的铜绿假单胞菌的活性。
Clin Microbiol Infect. 2010 Sep;16(9):1482-7. doi: 10.1111/j.1469-0691.2009.03130.x.
8
Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study.多利培南与亚胺培南静脉输注治疗呼吸机相关性肺炎的疗效与安全性：一项多中心随机研究
Crit Care Med. 2008 Apr;36(4):1089-96. doi: 10.1097/CCM.0b013e3181691b99.
9
Mucoid Pseudomonas in cystic fibrosis.囊性纤维化中的黏液样铜绿假单胞菌。
Am J Clin Pathol. 2007 Jul;128(1):32-4. doi: 10.1309/KJRPC7DD5TR9NTDM.
10
Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.哌拉西林-他唑巴坦治疗铜绿假单胞菌感染：延长输注给药策略的临床意义
Clin Infect Dis. 2007 Feb 1;44(3):357-63. doi: 10.1086/510590. Epub 2007 Jan 2.